DermoScan and SciBase to co-promote integrated workflow solution for Digital Dermoscopy and Nevisense
DermoScan is one of Europe’s foremost manufacturers of digital dermoscopy systems. The agreement means that EIS measurements from Nevisense will be integrated as a standard option in DermoGenius ultra. The result is that both patient data and Nevisense (EIS) measurements can be shared between the two systems. The solution improves both the clinic workflow and the diagnostic process for dermatology clinics.
- We are very happy to reach an agreement to cooperate with the team at SciBase. Nevisense is an exciting new technology that complements perfectly our digital dermoscopy system DermoGenius Ultra. Integrating the products will help save time and improve patient flow for our customers. We are also looking forward to cooperating in the market with joint sales and marketing activities, says Johann Tillmann, President of DermoScan.
DermoScan and SciBase will conduct joint marketing efforts of the integrated solution. Through DermoScan’s large customer base, SciBase will have the possibility to better reach key target groups and DermoScan will be able to offer a unique integration with Nevisense.
- The partnership with DermoScan is important to SciBase for two reasons - it gives us the opportunity to reach out to a larger audience and it means that we can deliver a better, more integrated solution for clinicians. We see the inclusion of Nevisense EIS as a parameter in the DermoGenius system as a sign of the growing interest in Nevisense and our method. We believe that DermoScan’s broad customer network will have positive effects on the market acceptance and penetration of Nevisense, says Simon Grant, CEO of SciBase.
Nevisense is a valuable complement to the visual assessment done with dermoscopy and so it is a clear advantage to integrate Nevisense and the EIS score into DermoGenius ultra. For the clinics, it will be easier to integrate Nevisense and the EIS score into their workflow. The integration with DermoGenius also makes it possible to connect Nevisense to the most common Electronic Health Record systems in Germany.
An Australian study, presented in August 2016, showed that the implementation of EIS can reduce the number of cases that needs to undergo sequential monitoring by almost half as well as being able to detect malignant melanomas by three months earlier than current methods.